Mereo BioPharma Group PLC ADR Cash Flow-to-Debt Ratio
Mereo BioPharma Group PLC ADR cash flow-to-debt ratio. Mereo BioPharma Group PLC ADR (MREO) has a Cash Flow-to-Debt Ratio of -1.00x as of June 2026, meaning its operating cash flow of $-6.04 Million could theoretically repay -1% of its total liabilities ($6.06 Million) in one year. Check MREO cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Mereo BioPharma Group PLC ADR (2015–2025)
Cash flow-to-debt ratio of Mereo BioPharma Group PLC ADR from 2015 to 2025. Historical debt coverage capacity for Mereo BioPharma Group PLC ADR across 11 annual periods. Check Mereo BioPharma Group PLC ADR cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Mereo BioPharma Group PLC ADR Cash Flow-to-Debt Ratio by Year (2015–2025)
Mereo BioPharma Group PLC ADR cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Mereo BioPharma Group PLC ADR. For the full cash flow conversion analysis, see MREO cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | $-30.97 Million | $5.00 Million | ▼ -190.9% |
| 2024 | -2.13x | $-32.83 Million | $15.42 Million | ▼ -60.8% |
| 2023 | -1.32x | $-21.13 Million | $15.96 Million | ▲ +29.5% |
| 2022 | -1.88x | $-48.82 Million | $26.01 Million | ▼ -1279.0% |
| 2021 | -0.14x | $-7.07 Million | $51.95 Million | ▲ +62.5% |
| 2020 | -0.36x | $-38.62 Million | $106.55 Million | ▲ +63.2% |
| 2019 | -0.98x | $-60.22 Million | $61.19 Million | ▼ -46.8% |
| 2018 | -0.67x | $-23.14 Million | $34.51 Million | ▲ +29.4% |
| 2017 | -0.95x | $-32.15 Million | $33.85 Million | ▲ +74.0% |
| 2016 | -3.65x | $-27.40 Million | $7.51 Million | ▼ -213.6% |
| 2015 | -1.16x | $-6.70 Million | $5.76 Million | — |